Patients using Novo Nordisk’s wildly popular weight-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a sight-threatening eye condition, according to data from a study published on Wednesday.
Tag Archive for: Rybelsus
Monthly medication subscription to the retailer’s virtual healthcare platform, Whole Health Rx, starts at an introductory price of $219, and does not require insurance, the company said in a statement.
The European Medicines Agency is set to review several diabetes and weight-loss treatments this week in connection with potential increased risk of suicidal ideation and self-harm, according to a draft agenda document of the agency’s Pharmacovigilance Risk Assessment Committee.
The European Medicines Agency recently flagged a safety signal related to GLP-1 receptor agonists and sent a list of questions to manufacturers including Novo Nordisk, Eli Lilly, Sanofi and AstraZeneca.
Novo Nordisk is the only company with FDA approval to sell semaglutide drugs. It said that the pharmacies are selling new drugs without FDA approval and claiming to compete with Novo Nordisk’s approved drugs, violating federal and state law.
A thyroid cancer safety signal was raised by the EU’s drugs watchdog last month over several Novo Nordisk (NOVOb.CO) products including semaglutide, which is used in popular diabetes and obesity medicines Ozempic and Wegovy.
Wegovy maker Novo Nordisk on Tuesday said it had sued some medical spas and wellness clinics in the United States for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss and diabetes drugs.
The FDA has warned that drug compounders are selling products that falsely claim to contain semaglutide, the same active ingredient as Novo Nordisk’s blockbuster diabetes and obesity drugs Ozempic and Wegovy their oral sibling Rybelsus.
Supply problems with the weight loss drug Wegovy were a stumbling block to growth, but Novo Nordisk has rallied.
Novo Nordisk has entered into an agreement to acquire Forma Therapeutics for $1.1 billion, the company announced Thursday.